ArticleFrontiers in cell and developmental biology2025
Identification of prognostic biomarkers related to epithelial-mesenchymal transition and anoikis in hepatocellular carcinoma using transcriptomics and single-cell sequencing.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma.Cellular and molecular life sciences : CMLS · 2026Article
- Corylin inhibits liver cancer cell growth through the endogenous apoptosis and mitophagy.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial-mesenchymal transition (EMT) and anoikis are critically associated with hepatocellular carcinoma (HCC). However, the precise mechanisms underlying their roles in HCC remain unclear. This study aims to explore the involvement of EMT-related genes (EMTRGs) and anoikis-related genes (ARGs) in HCC. Methods: Data from TCGA-HCC, ICGC-LIPI - JP, GSE149614, EMTRGs and ARGs were utilised in this study. It utilised single-cell RNA sequencing for cell sorting. Biomarkers were identified through analyses such as differential expression analysis and weighted gene co-expression network analysis (WGCNA). The risk model and nomogram were constructed based on biomarkers. Subsequently, the potential functions of biomarkers were explored through methods such as enrichment analysis and immune microenvironment analysis. Finally, to confirm the expression of these biomarkers in different prognostic groups, gene expression levels were quantified using real-time quantitative polymerase chain reaction (RT-qPCR). Results: LAMA4, C7, KPNA2, STMN1, and SF3B4 were identified as biomarkers. The risk score emerged as an independent prognostic factor for patients with HCC. The nomogram showed that these five biomarkers had good predictive ability for the 1-, 3-, and 5-year survival rates of HCC patients. Drug sensitivity analysis revealed significant associations between the IC50 values of 23 drugs and risk scores. In the GSE149614 dataset, most biomarkers were predominantly expressed in stromal cells (endothelial cells and fibroblasts). In TCGA-HCC, all genes, except C7, were upregulated in the HCC samples. RT-qPCR analysis revealed statistically significant upregulation of STMN1 and SF3B4 transcripts in the HCC group, consistent with TCGA-HCC dataset. Conclusion: This study identified five EMTRGs and ARGs (LAMA4, C7, KPNA2, STMN1, and SF3B4) as biomarkers of HCC, offering new insights for further research in HCC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.